flutamide has been researched along with Bladder Cancer in 9 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| " UFT (a compound of tegafur and uracil) is said to be effective for bladder cancer." | 4.80 | [Progress in oral anti-cancer drug therapy for urological cancer]. ( Akaza, H; Tsukamoto, S, 1999) |
| ", UMUC3-AR-short hairpin RNA [shRNA], TCCSUP-AR-shRNA, 647V) bladder cancer lines treated with dihydrotestosterone and each AR antagonist." | 3.83 | Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth. ( El-Shishtawy, KA; Ide, H; Kashiwagi, E; Kawahara, T; Li, Y; Miyamoto, H; Reis, LO; Zheng, Y, 2016) |
| "The present study describes the role of the ubiquitin ligase Siah-2 and corepressor N-CoR in controlling androgen receptor (AR) and estrogen receptors (ERα and ERβ) signaling in an appropriate animal model (Fischer 344 female rats) of non-muscle invasive bladder cancer (NMIBC), especially under conditions of anti-androgen therapy with flutamide." | 3.81 | Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer. ( Apolinário, LM; Böckelmann, PK; da Silva Nunes, I; Duran, N; Fávaro, WJ; Garcia, PV, 2015) |
| "05% BBN [N-butyl-N-(4-hydroxybutyl)nitrosamine] orally to 117 Wistar rats for 10 weeks, divided them into seven groups-control, surgical castration, finasteride (2 mg/kg), luteinizing hormone releasing hormone (LH-RH) agonist (1 mg/kg) flutamide (50 mg/kg), LH-RH agonist plus finasteride, and LH-RH agonist plus flutamide-, and then cystectomized them to investigate the incidence of bladder cancer on week 21; experiment 2: we administered 0." | 3.69 | Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. ( Akaza, H; Ami, Y; Ideyama, Y; Imada, S; Koiso, K; Takenaka, T, 1997) |
| "Dihydrotestosterone (DHT) treatment in SVHUC-AR reduced mRNA expression of all the UGT1A subtypes (19-75% decrease), and hydroxyflutamide antagonized the DHT effects." | 1.39 | Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis. ( Chang, C; Hsu, JW; Izumi, K; Miyamoto, H; Zheng, Y, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ide, H | 2 |
| Inoue, S | 1 |
| Mizushima, T | 1 |
| Jiang, G | 1 |
| Chuang, KH | 1 |
| Oya, M | 1 |
| Miyamoto, H | 3 |
| Garcia, PV | 1 |
| Apolinário, LM | 1 |
| Böckelmann, PK | 1 |
| da Silva Nunes, I | 1 |
| Duran, N | 1 |
| Fávaro, WJ | 1 |
| Shang, Z | 1 |
| Li, Y | 2 |
| Zhang, M | 1 |
| Tian, J | 1 |
| Han, R | 1 |
| Shyr, CR | 1 |
| Messing, E | 1 |
| Yeh, S | 1 |
| Niu, Y | 1 |
| Chang, C | 2 |
| Kawahara, T | 1 |
| Kashiwagi, E | 1 |
| El-Shishtawy, KA | 1 |
| Reis, LO | 1 |
| Zheng, Y | 2 |
| Izumi, K | 1 |
| Hsu, JW | 1 |
| Chen, F | 1 |
| Langenstroer, P | 1 |
| Zhang, G | 1 |
| Iwamoto, Y | 1 |
| See, W | 1 |
| Imada, S | 2 |
| Akaza, H | 3 |
| Otani, M | 1 |
| Koiso, K | 2 |
| Ami, Y | 1 |
| Ideyama, Y | 1 |
| Takenaka, T | 1 |
| Tsukamoto, S | 1 |
1 review available for flutamide and Bladder Cancer
| Article | Year |
|---|---|
[Progress in oral anti-cancer drug therapy for urological cancer].
Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Drug Administration Sch | 1999 |
8 other studies available for flutamide and Bladder Cancer
| Article | Year |
|---|---|
Androgen Receptor Signaling Reduces Radiosensitivity in Bladder Cancer.
Topics: Androgen Receptor Antagonists; Animals; Cell Line, Tumor; Cell Proliferation; DNA Breaks, Double-Str | 2018 |
Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Androgen Antagonists; Animals; Antineoplastic Combined Chemotherapy Pr | 2015 |
Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.
Topics: Androgen Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Cell Lin | 2015 |
Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tu | 2016 |
Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Animals; Cell Line; Cystectomy; Dihydrotestosterone; | 2013 |
Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines.
Topics: Androgen Antagonists; Anilides; Autocrine Communication; BCG Vaccine; Carcinoma, Transitional Cell; | 2003 |
[Effects of androgen regulation system on bladder carcinogenesis in male mice].
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Animals; Butylhydroxybutylnitrosamine; Finasteri | 1995 |
Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats.
Topics: Administration, Oral; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic | 1997 |